Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.34Last Year’s EPS
0.31Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed a largely positive operational and financial story: robust revenue and volume growth, strong margins and cash generation, successful transition to a lower-cost transcriptome platform, substantial clinical evidence and data assets, and a clear product launch roadmap (TrueMRD and Prosigna) that sets up multi-year growth. Headwinds and risks were acknowledged—one-time prior-period collections (PPCs) amplified 2025 results and complicate comparability; planned investments and launch-related spending will temper margins in 2026; reimbursement timelines and near-term revenue contribution for new products (MRD, Prosigna, Percepta/NIGHTINGALE) remain uncertain. On balance, the highlights (top-line momentum, margins, cash, platform readiness, evidence generation, and pipeline) significantly outweigh the lowlights, which are mostly timing, one-time, or investment-related risks.Company Guidance
Strong Revenue Growth
Q4 total revenue of $140.6M (management also cited ~$141M) representing 19% year-over-year growth; full-year 2025 revenue of $517M, up 16% year-over-year and at the high end of preliminary range.
Testing Revenue and Volume Expansion
Q4 testing revenue of $135.8M, up 21% YoY; total testing volume ~48,000 tests in Q4 (+16% YoY) and testing volume ~45,500 tests (+16% YoY). Afirma Q4 volume ~18,250 tests (+12% YoY); Decipher Q4 volume ~27,200 tests and marked the 15th consecutive quarter of >20% YoY volume growth.
Improving ASP and Gross Margin
Testing ASP of ~$2,984 in Q4, +4% YoY (normalized ASP $2,875, +1% YoY after PPC adjustment). Non-GAAP gross margin of 75.1% in Q4 (up 580 bps YoY); testing gross margin 76.1% (up 380 bps YoY), driven by operational efficiencies (v2 transcriptome) and PPCs.
Industry-Leading Profitability and Cash Generation
Adjusted EBITDA Q4 $42.3M (30.1% of revenue); full-year adjusted EBITDA margin 27.6% (exceeding 25% target more than a year ahead). GAAP net income Q4 $41.1M and $66.4M for FY2025. Generated $52.6M of cash from operations in Q4 and ended the quarter with $412.9M cash and cash equivalents; cash balance increased by >$120M over the year.
Platform Execution and Operational Efficiency
Completed full transition of Afirma to the more scalable, lower-cost v2 transcriptome (lower no-result rate: 2% improvement Q/Q), restructured Veracyte SAS, and fully moved Afirma volume to v2 enabling better throughput and cost structure.
Decipher Clinical Momentum and Adoption
Decipher ordering physicians increased 18% YoY in Q4; >300,000 prostate patients tested since launch with >100,000 tested in 2025 alone. Management cites ~33% market penetration for Decipher and forecasts sustained double-digit growth (Decipher revenue grew 27% in the quarter).
Evidence and Research Engine
Substantial publication and abstract activity: Decipher prostate >100 clinical utility/validity publications plus ~100 GRID research publications; numerous ASCO GU abstracts for prostate and bladder; Afirma GRID research continues to drive publications—supporting adoption and future product additions (new signatures).
Product Pipeline and Launches Scheduled for 2026
Two major product launches planned in 2026: TrueMRD (whole-genome MRD for muscle invasive bladder cancer) targeted H1 launch after MolDX technical assessment, and Prosigna LDT (PAM50) planned for U.S. launch over the summer on the new transcriptome workflow.
Digital Pathology and Data Assets
Implemented slide scanning as standard production workflow: scanned >210,000 slides from >150,000 patients with outcomes data, creating a large combined digital pathology + transcriptome dataset for future AI and biomarker development.
2026 Guidance Reiteration with Growth Targets
Reiterated 2026 revenue guidance of $570M–$582M (10%–13% YoY); testing revenue growth guidance of 14%–16% with Decipher ~20% growth and Afirma mid- to high-single-digit revenue growth; adjusted EBITDA margin targeted at ~25% for 2026.
VCYT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VCYT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $35.72 | ― | ― |
Nov 04, 2025 | $36.12 | $46.04 | +27.46% |
Aug 06, 2025 | $23.97 | $27.68 | +15.48% |
May 07, 2025 | $30.84 | $31.21 | +1.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Veracyte (VCYT) report earnings?
Veracyte (VCYT) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Veracyte (VCYT) earnings time?
Veracyte (VCYT) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCYT EPS forecast?
VCYT EPS forecast for the fiscal quarter 2026 (Q1) is 0.34.